Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GCK | P35557 | 2/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666576 | 0.88 | PLA2G2A (0.47) | PLA2G2AMAPTCNR1CNR2SMN1; SMN2 | |
| SCHEMBL2771698 | 0.86 | MAPT (0.58) | PLA2G2AMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL12806374 | 0.86 | PLA2G2A (0.50) | PLA2G2AMAPTCNR1CNR2KDM4E | |
| SCHEMBL10268140 | 0.85 | PLA2G2A (0.55) | PLA2G2AMAPTCNR1CNR2SMN1; SMN2 | |
| SCHEMBL2667066 | 0.85 | PLA2G2A (0.47) | PLA2G2AMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1107694 | 0.84 | CA1 (0.50) | KDM4EALDH1A1TSHR | |
| SCHEMBL13461247 | 0.84 | PLA2G2A (0.54) | PLA2G2AMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL2666575 | 0.83 | PLA2G2A (0.43) | PLA2G2AMAPTCNR1CNR2RAB9A | |
| SCHEMBL25327393 | 0.83 | PLA2G2A (0.71) | PLA2G2AMAPTCNR1CNR2TSHR | |
| SCHEMBL15731932 | 0.83 | PLA2G2A (0.71) | PLA2G2AMAPTCNR1CNR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| EP-1529530-B3 | Compounds affecting glucokinase | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1568367-B3 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| EP-1987831-A1 | COMPOUNDS EFFECTING GLUCOKINASE | AstraZeneca AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1669069-B1 | Compounds effecting glukokinase | ASTRAZENECA AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1661568-B1 | Compounds effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1695705-B1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1661569-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1420784-B1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1568367-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1529530-A1 | Compounds affecting glucokinase | AstraZeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050080106-A1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | US | disclosed |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1420784-A1 | COMPOUNDS EFFECTING GLUCOKINASE | Astrazeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1404335-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | Astrazeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003015774-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003000267-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080106-A1 | Compounds effecting glucokinase | GCKR, GCK, SLC5A2 | PLA2G2A 3793/4885MAPT 4022/4885CNR1 978/4885 |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | GCK, GCKR, NADK | PLA2G2A 3373/4885MAPT 3610/4885CNR1 453/4885 |
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | PLA2G2A 3793/4885MAPT 4022/4885CNR1 978/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | PLA2G2A 3793/4885MAPT 4022/4885CNR1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.